ESMO 2024 Highlights: Presenter Vignette – Nicolas Girard

Prof. Nicolas Girard

Nicolas Girard

MD, PhD

Institut Curie

Abstract# LBA53

Nivolumab (NIVO) plus relatlimab with platinum-doublet chemotherapy (PDCT) vs NIVO + PDCT as first-line (1L) treatment (tx) for stage IV or recurrent NSCLC: results from the randomized phase 2 RELATIVITY-104 study